<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Vyas A</submitter><funding>BLRD VA</funding><funding>NIDCR NIH HHS</funding><funding>Office of Extramural Research, National Institutes of Health</funding><funding>NCI NIH HHS</funding><funding>U.S. Department of Veterans Affairs</funding><funding>NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>e2100670119</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8944912</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>119(12)</volume><pubmed_abstract>Squamous cell carcinoma of the head and neck (SCCHN) is a devastating disease that continues to have low cure rates despite the recent advances in therapies. Cisplatin is the most used chemotherapy agent, and treatment failure is largely driven by resistance to this drug. Amplification of chromosomal band 11q13 occurs in ∼30% of SCCHN tumors. This region harbors the ANO1 gene that encodes the TMEM16A ion channel, which is responsible for calcium-activated chloride transport in epithelial tissues. TMEM16A overexpression is associated with cisplatin resistance, and high TMEM16A levels correlate with decreased survival. However, the mechanistic underpinning of this effect remains unknown. Lysosomal biogenesis and exocytosis have been implicated in cancer because of their roles in the clearanc</pubmed_abstract><journal>Proceedings of the National Academy of Sciences of the United States of America</journal><pubmed_title>Lysosomal inhibition sensitizes TMEM16A-expressing cancer cells to chemotherapy.</pubmed_title><pmcid>PMC8944912</pmcid><funding_grant_id>R01 DE027185</funding_grant_id><funding_grant_id>I01 BX003456</funding_grant_id><funding_grant_id>P50 CA097190</funding_grant_id><funding_grant_id>R35 GM119412</funding_grant_id><funding_grant_id>R01 DE028343</funding_grant_id><funding_grant_id>S10 OD019973</funding_grant_id><funding_grant_id>R35GM119412</funding_grant_id><pubmed_authors>Vyas A</pubmed_authors><pubmed_authors>Villanueva H</pubmed_authors><pubmed_authors>Rajagopalan P</pubmed_authors><pubmed_authors>Hammond GRV</pubmed_authors><pubmed_authors>Kiselyov K</pubmed_authors><pubmed_authors>Pacheco J</pubmed_authors><pubmed_authors>Duvvuri U</pubmed_authors><pubmed_authors>Basu D</pubmed_authors><pubmed_authors>Cruz-Rangel S</pubmed_authors><pubmed_authors>Gomez-Casal R</pubmed_authors><pubmed_authors>Sikora AG</pubmed_authors></additional><is_claimable>false</is_claimable><name>Lysosomal inhibition sensitizes TMEM16A-expressing cancer cells to chemotherapy.</name><description>Squamous cell carcinoma of the head and neck (SCCHN) is a devastating disease that continues to have low cure rates despite the recent advances in therapies. Cisplatin is the most used chemotherapy agent, and treatment failure is largely driven by resistance to this drug. Amplification of chromosomal band 11q13 occurs in ∼30% of SCCHN tumors. This region harbors the ANO1 gene that encodes the TMEM16A ion channel, which is responsible for calcium-activated chloride transport in epithelial tissues. TMEM16A overexpression is associated with cisplatin resistance, and high TMEM16A levels correlate with decreased survival. However, the mechanistic underpinning of this effect remains unknown. Lysosomal biogenesis and exocytosis have been implicated in cancer because of their roles in the clearanc</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Mar</publication><modification>2026-06-18T05:44:26.306Z</modification><creation>2025-04-04T20:50:52.815Z</creation></dates><accession>S-EPMC8944912</accession><cross_references><pubmed>35286200</pubmed><doi>10.1073/pnas.2100670119</doi></cross_references></HashMap>